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Human mesenchymal stem/stromal cells (MSC) are promising candidates for cell
based therapies and the development of microcarrier-based MSC cultures in
scalable stirred bioreactors combined with well-defined serum-/xenogeneic (xeno)free medium formulations represent important milestones for the clinical-scale
production of human MSC. In this work, we optimized our previously established
xeno-free microcarrier-based culture system, towards the large-scale production
of human bone marrow (BM)-derived MSC and adipose tissue-derived
stem/stromal cells (ASC) and we have established a stirred culture system
combining gelatin-based microcarriers and xeno-free culture medium for the
expansion of umbilical cord matrix (UCM)-derived MSC. In addition, we tested the
ability of using a human platelet lysate-based culture supplement to effectively
isolate MSC from UCM, as well as to expand these cells under stirred conditions
using plastic microcarriers.
By rationally changing the seeding protocol in BM MSC and ASC stirred cultures,
initial cell adhesion was successfully increased from 30-40% to approximately
95%. The maximization of initial cell adhesion combined with an optimized feeding
regimen in the first days of culture led to higher final cell densities in a shorter
culture period (7 versus 14 days) compared to our previous report. To enhance the
scalability of this xeno-free system, ready-to-use microcarriers Synthemax® II and
Enhanced Attachment® were evaluated in comparison to the previously tested precoated plastic microcarriers. BM MSC cultures using these beads attained final cell
densities identical to cultures with pre-coated plastic microcarriers, demonstrating
that ready-to-use microcarriers can be advantageous alternatives for this xenofree microcarrier-based culture system. When using UCM MSC, cell expansion in
the spinner flaks enabled the production of 240,000 cells per mL after 5 days of
culture (5 - fold) with xeno-free culture medium. The optimized protocol was then
successfully scaled-up to a stirred-tank bioreactor yielding 120 million cells.
We also demonstrate that a human platelet lysate-based product can be an
effective supplement for the successful isolation and scalable expansion of UCM
MSC under stirred conditions. Upon an initial 54% cell adhesion to plastic beads,
UCM MSC were able to expand by > 13 fold after 5-6 days in culture.
Importantly, all expanded cells maintained their characteristic immunophenotype,
multilineage differentiation potential and hematopoietic stem/progenitor cell
supportive capacity.
We anticipate that this microcarrier-based culture platforms will enable a cost
effective, reproducible protocol for the efficient manufacturing of MSC from
different human sources, for potential applications in Regenerative Medicine and
Cell Therapy settings.

